Carboplatin for Non-Small Cell Lung Cancer

SUNY Upstate Medical University, Syracuse, NY
Non-Small Cell Lung CancerCarboplatin - Drug
All Sexes

Study Summary

This trial is testing a new treatment for patients with early stage lung cancer who cannot have surgery. The goal is to see if it is a good option for these patients.

Eligible Conditions
  • Non-Small Cell Lung Cancer

Treatment Effectiveness

Phase-Based Effectiveness

1 of 3
Phase < 1

Study Objectives

1 Primary · 6 Secondary · Reporting Duration: 24 months

24 months
PET/CT scan
Local progression as measured by PET/CT
Overall survival as determined by patient contact
Radiographic response as measured by PET/CT
Regional progression as measured by PET/CT
Time to overall progressions as measured by PET/CT
Toxicity as measured using the National Cancer Institute's Common Terminology Criteria for Adverse Events

Trial Safety

Phase-Based Safety

1 of 3

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.
No Placebo Group
All patients enrolled in this trial will receive the new treatment.

Trial Design

1 Treatment Group

Chemotherapy with hypofractionated RT
1 of 1

Experimental Treatment

12 Total Participants · 1 Treatment Group

Primary Treatment: Carboplatin · No Placebo Group · Phase < 1

Chemotherapy with hypofractionated RTExperimental Group · 3 Interventions: Carboplatin, Paclitaxel, 70 Gy in 20 fractions over 4 weeks · Intervention Types: Drug, Drug, Radiation
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 24 months

Who is running the clinical trial?

State University of New York - Upstate Medical UniversityLead Sponsor
157 Previous Clinical Trials
27,040 Total Patients Enrolled
Michael Mix, MDPrincipal InvestigatorState University of New York - Upstate Medical University

Eligibility Criteria

Age 18+ · All Participants · 1 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You must be eligible for a specific type of radiation treatment called hypofractionated radiation therapy.

Frequently Asked Questions

What maladies has Paclitaxel been traditionally prescribed for?

"Paclitaxel is the go-to medication for treating melanoma. Moreover, it can also assist with other diseases such as metastasized neoplasms, lymphomas, non-Hodgkin's malignancies and advanced sarcoma." - Anonymous Online Contributor

Unverified Answer

Are there still openings for volunteers in this trial?

"This clinical study, initially released on December 1st 2014 and most recently updated May 1th 2018, is seeking participants. has the information available for public viewing." - Anonymous Online Contributor

Unverified Answer

How many participants are enrolled in this investigation?

"Affirmative. The clinical trial directory on shows that recruitment for this medical study is active - it was initially posted on December 1st 2014 and its information has been recently updated as of May 1st 2018. At present, 12 participants need to be found from a single clinic site." - Anonymous Online Contributor

Unverified Answer

Has Paclitaxel been evaluated in other clinical trials?

"At present, there are 1175 active Paclitaxel studies with 332 of those in the 3rd phase. Notably, Shanghai alone has several clinical trials while globally 66531 different locations have a trial running for this medication." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.